NEOPLASMS BY HISTOLOGIC TYPE

This early-stage study is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and tolerable for patients. It focuses on adults with acute myeloid leukemia that has returned or not responded to prior treatment and has specific gene…

This early-stage trial is testing the safety of a new gene therapy called KLN-1010 for people with multiple myeloma that has returned or stopped responding to other treatments. The therapy works by modifying the patient's own immune cells inside the body to better target cancer c…

This trial is testing if a drug called alectinib, already approved for a type of lung cancer, can help treat other rare cancers that share the same genetic change (ALK mutation). It will involve about 30 adults and children with various rare or hard-to-treat cancers. The goal is …

This trial is testing if a drug called capmatinib, already used for some lung cancers, can help adults with rare or uncommon cancers that have specific changes in a gene called MET. The goal is to see if the drug shrinks tumors or provides long-term benefit for these hard-to-trea…

This trial is testing if an existing immunotherapy drug called atezolizumab can help control rare cancers or common cancers with rare genetic features. It will involve about 30 adults and children whose cancers have specific genetic markers. The goal is to see if this approved dr…

This study is testing the safety of an experimental virus therapy called G207 for children and young adults with recurrent or hard-to-treat brain tumors in the cerebellum. The virus is designed to infect and kill cancer cells while sparing healthy ones. Researchers will also test…

This trial is testing if a drug called entrectinib, already approved for some lung cancers, can help control other rare cancers that share the same genetic change (called ROS1-positive). It aims to enroll about 30 adults and children with these rare cancers to see if the drug shr…